[
  {
    "ts": null,
    "headline": "Healthcare Stocks Declined Ahead of Jobs Report -- Healthcare Roundup",
    "summary": "Healthcare Stocks Declined Ahead of Jobs Report -- Healthcare Roundup",
    "url": "https://finnhub.io/api/news?id=36fa0c55e33f37a7c8d1488d1bcea9802b0d930d96141208081e6dd878a4a1f0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751476980,
      "headline": "Healthcare Stocks Declined Ahead of Jobs Report -- Healthcare Roundup",
      "id": 135981342,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Healthcare Stocks Declined Ahead of Jobs Report -- Healthcare Roundup",
      "url": "https://finnhub.io/api/news?id=36fa0c55e33f37a7c8d1488d1bcea9802b0d930d96141208081e6dd878a4a1f0"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment",
    "summary": "Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.",
    "url": "https://finnhub.io/api/news?id=ed56eadbe30ee0f5dd759247e0d0f514dc21df07d29e53fcce4389e3ccabc27f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751471100,
      "headline": "Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment",
      "id": 135714301,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.",
      "url": "https://finnhub.io/api/news?id=ed56eadbe30ee0f5dd759247e0d0f514dc21df07d29e53fcce4389e3ccabc27f"
    }
  },
  {
    "ts": null,
    "headline": "Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma",
    "summary": "Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer Approval based on pivotal Phase 1/2 LINKER-MM1 trial; results reported were among the highest overall (70%) and complete response rates (45%) for bispecific antibodies in heavily pre-treated multiple myeloma patients Lynozyfic provides a patient-centric response-adapted dosing regimenTARRYTOWN, N.Y., July 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharma",
    "url": "https://finnhub.io/api/news?id=f5cb50df730f58bd720b2076271a524da901d20a6bf65c6f93e438239dd375cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751468400,
      "headline": "Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma",
      "id": 135714302,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer Approval based on pivotal Phase 1/2 LINKER-MM1 trial; results reported were among the highest overall (70%) and complete response rates (45%) for bispecific antibodies in heavily pre-treated multiple myeloma patients Lynozyfic provides a patient-centric response-adapted dosing regimenTARRYTOWN, N.Y., July 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharma",
      "url": "https://finnhub.io/api/news?id=f5cb50df730f58bd720b2076271a524da901d20a6bf65c6f93e438239dd375cc"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myelomac",
    "summary": "Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted accelerated approval for Lynozyfic?? to treat adult patients with relapsed or refractory multiple...",
    "url": "https://finnhub.io/api/news?id=e89948f8a89f005c14ef1681eac6338a3a8cd449903ba2bdb9793fa81d9d20c0",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751463411,
      "headline": "Regeneron Pharmaceuticals, Inc. Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myelomac",
      "id": 135714600,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted accelerated approval for Lynozyfic?? to treat adult patients with relapsed or refractory multiple...",
      "url": "https://finnhub.io/api/news?id=e89948f8a89f005c14ef1681eac6338a3a8cd449903ba2bdb9793fa81d9d20c0"
    }
  },
  {
    "ts": null,
    "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "url": "https://finnhub.io/api/news?id=6da51c27504d8fc46d28c9c28bf3eb6253da389e1de9f77e5f4da4bf5ff12cbd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751461203,
      "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
      "id": 135714303,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
      "url": "https://finnhub.io/api/news?id=6da51c27504d8fc46d28c9c28bf3eb6253da389e1de9f77e5f4da4bf5ff12cbd"
    }
  },
  {
    "ts": null,
    "headline": "US FDA approves Regeneron's blood cancer therapy",
    "summary": "The U.S. Food and Drug Administrationhas approved Regeneron's cancer therapy, the companysaid on Wednesday, providing another treatment option forpatients with a recurring and common form of blood...",
    "url": "https://finnhub.io/api/news?id=b1ea610cbb9ea3b8083dcb485711169aba7c34df5fe4ac91abbc9ea40ae5c916",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751455509,
      "headline": "US FDA approves Regeneron's blood cancer therapy",
      "id": 135713163,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "The U.S. Food and Drug Administrationhas approved Regeneron's cancer therapy, the companysaid on Wednesday, providing another treatment option forpatients with a recurring and common form of blood...",
      "url": "https://finnhub.io/api/news?id=b1ea610cbb9ea3b8083dcb485711169aba7c34df5fe4ac91abbc9ea40ae5c916"
    }
  }
]